271 related articles for article (PubMed ID: 33028137)
21. Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer.
Annunziata MC; De Stefano A; Fabbrocini G; Leo S; Marchetti P; Romano MC; Romano I
Clin Drug Investig; 2019 Sep; 39(9):825-834. PubMed ID: 31264159
[TBL] [Abstract][Full Text] [Related]
22. [Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
Tjin-A-ton ML; van Montfrans C; Koldenhof JJ; Sigurdsson V; Voest EE; Witteveen PO
Ned Tijdschr Geneeskd; 2007 Apr; 151(17):945-52. PubMed ID: 17520845
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines].
Fernández-Guarino M; Pérez García B; Aldanondo Fernández de la Mora I; García-Millán C; Garrido López P; Jaén Olasolo P
Actas Dermosifiliogr; 2006 Oct; 97(8):503-8. PubMed ID: 17067527
[TBL] [Abstract][Full Text] [Related]
24. Adverse cutaneous effects of neratinib.
Hamid RN; Ahn CS; Huang WW
J Dermatolog Treat; 2019 Aug; 30(5):487-488. PubMed ID: 30321080
[TBL] [Abstract][Full Text] [Related]
25. [Skin signs associated with epidermal growth factor inhibitors].
Hannoud S; Rixe O; Bloch J; Le Pelletier F; Lebrun-Vignes B; Doarika A; Khayat D; Chosidow O
Ann Dermatol Venereol; 2006 Mar; 133(3):239-42. PubMed ID: 16800173
[TBL] [Abstract][Full Text] [Related]
26. Skin Toxicities During Colorectal Cancer Chemotherapy: Incidence and Pearls of Treatment in Our Experience.
Panariello L; Donnarumma M; Iaffaioli RV; Chiodini P; Annunziata MC; Peduto T; Fabbrocini G
Clin Colorectal Cancer; 2020 Dec; 19(4):e235-e242. PubMed ID: 32665093
[TBL] [Abstract][Full Text] [Related]
27. Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study.
Yen CF; Hsu CK; Yang HS; Lee CN; Chi CC; Chung WH; Wang CL; Pang JS; Wang CW; Ko YS; Lu CW
Int J Dermatol; 2020 Mar; 59(3):326-332. PubMed ID: 31763692
[TBL] [Abstract][Full Text] [Related]
28. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
Chayahara N; Mukohara T; Tachihara M; Fujishima Y; Fukunaga A; Washio K; Yamamoto M; Nakata K; Kobayashi K; Takenaka K; Toyoda M; Kiyota N; Tobimatsu K; Doi H; Mizuta N; Marugami N; Kawaguchi A; Nishigori C; Nishimura Y; Minami H
Oncologist; 2019 Jul; 24(7):885-e413. PubMed ID: 30890624
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous toxicities of epidermal growth factor receptor inhibitors: A prospective study in 60 Asian patients.
Chularojanamontri L; Tuchinda P; Likitwattananurak C; Pongparit K; Rujitharanawong C; Ithimakin S; Kulthanan K
Asian Pac J Allergy Immunol; 2019 Mar; 37(1):12-18. PubMed ID: 29549700
[TBL] [Abstract][Full Text] [Related]
30. Assessment of skin-related toxicity in patients with metastatic colorectal cancer treated with cetuximab.
Pacek A; Kozioł M; Püsküllüoğlu M; Tomaszewski KA; Ochenduszko S; Zygulska AL; Krzemieniecki K
Acta Dermatovenerol Croat; 2014; 22(2):137-44. PubMed ID: 25102801
[TBL] [Abstract][Full Text] [Related]
31. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections.
Braden RL; Anadkat MJ
Support Care Cancer; 2016 Sep; 24(9):3943-50. PubMed ID: 27117557
[TBL] [Abstract][Full Text] [Related]
32. Cetuximab-induced cutaneous toxicity.
Tomková H; Kohoutek M; Zábojníková M; Pospísková M; Ostrízková L; Gharibyar M
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):692-6. PubMed ID: 19925598
[TBL] [Abstract][Full Text] [Related]
33. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
34. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer.
Pinta F; Ponzetti A; Spadi R; Fanchini L; Zanini M; Mecca C; Sonetto C; Ciuffreda L; Racca P
Clin Colorectal Cancer; 2014 Mar; 13(1):62-7. PubMed ID: 24332355
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Cancer Med; 2019 Aug; 8(9):4169-4175. PubMed ID: 31199595
[TBL] [Abstract][Full Text] [Related]
36. Targeted agents: management of dermatologic toxicities.
Burtness B
J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):793-6. PubMed ID: 24853219
[TBL] [Abstract][Full Text] [Related]
37. Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients.
Ibraheim MK; Lo J; Gupta R; Parseghian C; Patel AB
Support Care Cancer; 2022 Oct; 30(10):8051-8058. PubMed ID: 35771289
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Case report.
D'Alessio A; Cecchini S; Di Mauro D; Geroli L; Villa S; Quadri A; Resta D; Fortugno C
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27791234
[TBL] [Abstract][Full Text] [Related]
39. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
40. Skin problems and EGFR-tyrosine kinase inhibitor.
Kozuki T
Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]